Trinity Biotech plc (TRIB)
After hours:
| Previous Close | 1.8400 |
| Open | 1.8950 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.8200 - 1.8950 |
| 52 Week Range | 1.7900 - 5.5000 |
| Volume | |
| Avg. Volume | 98,469 |
| Market Cap | 13.984M |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.9600 |
| Earnings Date | Apr 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jun 05, 2015 |
| 1y Target Est | N/A |
Insider MonkeyTrinity Biotech plc (NASDAQ:TRIB) Q4 2023 Earnings Call Transcript
Trinity Biotech plc (NASDAQ:TRIB) Q4 2023 Earnings Call Transcript April 4, 202 Trinity Biotech plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings! Welcome to the Trinity Biotech’s Fourth Quarter and Full Year 2023 Earnings Conference Call. At this […]
- GuruFocus.com
Trinity Biotech PLC (TRIB) Q4 2023 Earnings Call Transcript Highlights: A Glimpse into ...
Trinity Biotech reveals Q4 results and strategic initiatives amidst a challenging fiscal year, setting the stage for a transformative 2024.
GlobeNewswireTrinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates. Business Updates Comprehensive Transformation Plan At the Emerging Growth Investor Conference on March 7, 2024, our new management team announced a comprehensive tra
